Search

Your search keyword '"Chuang GY"' showing total 113 results

Search Constraints

Start Over You searched for: Author "Chuang GY" Remove constraint Author: "Chuang GY"
113 results on '"Chuang GY"'

Search Results

1. Design of soluble HIV-1 envelope trimers free of covalent gp120-gp41 bonds with prevalent native-like conformation.

2. Cholesterol reduction by immunization with a PCSK9 mimic.

3. mtx-COBRA: Subcellular localization prediction for bacterial proteins.

4. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.

5. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge.

6. Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.

7. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.

8. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant.

9. Structure of an influenza group 2-neutralizing antibody targeting the hemagglutinin stem supersite.

10. C 3 -Symmetric Aromatic Core of Griffithsin Is Essential for Potent Anti-HIV Activity.

11. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.

12. Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2.

13. GLYCO: a tool to quantify glycan shielding of glycosylated proteins.

14. Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.

15. Extended antibody-framework-to-antigen distance observed exclusively with broad HIV-1-neutralizing antibodies recognizing glycan-dense surfaces.

16. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies.

17. Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.

18. Blocking α 4 β 7 integrin delays viral rebound in SHIV SF162P3 -infected macaques treated with anti-HIV broadly neutralizing antibodies.

19. N-terminal Transmembrane-Helix Epitope Tag for X-ray Crystallography and Electron Microscopy of Small Membrane Proteins.

20. Structural basis of LAIR1 targeting by polymorphic Plasmodium RIFINs.

21. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.

22. Sequence-Signature Optimization Enables Improved Identification of Human HV6-1-Derived Class Antibodies That Neutralize Diverse Influenza A Viruses.

23. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.

24. Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria.

25. Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.

26. Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants.

27. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.

28. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.

29. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth.

30. Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes.

31. Cryo-EM Structures of SARS-CoV-2 Spike without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of Receptor-Binding Domains.

32. Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains.

33. Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies.

34. Identification and Structure of a Multidonor Class of Head-Directed Influenza-Neutralizing Antibodies Reveal the Mechanism for Its Recurrent Elicitation.

35. Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature.

36. Cryo-EM Structures Delineate a pH-Dependent Switch that Mediates Endosomal Positioning of SARS-CoV-2 Spike Receptor-Binding Domains.

37. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.

38. VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.

39. Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition.

40. BCrystal: an interpretable sequence-based protein crystallization predictor.

41. Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen.

42. Removal of variable domain N -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies.

43. Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B.

44. Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields.

45. Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates.

46. Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.

47. Endothelial Targeted Strategies to Combat Oxidative Stress: Improving Outcomes in Traumatic Brain Injury.

48. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.

49. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual.

50. Improvement of antibody functionality by structure-guided paratope engraftment.

Catalog

Books, media, physical & digital resources